Evidence map›Paper›PMID 35418487›Full record

ReviewEuropean respiratory review : an official journal of the European Respiratory Society2022

Incidental discovery of interstitial lung disease: diagnostic approach, surveillance and perspectives.

Sara Tomassetti, Venerino Poletti, Claudia Ravaglia, Nicola Sverzellati, Sara Piciucchi, Diletta Cozzi, Valentina Luzzi, Camilla Comin, Athol U Wells

Erratum issuedOpen access · diamondAbstract readReview
In one paragraph

Review in European respiratory review : an official journal of the European Respiratory Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 49 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Current perspectives on interstitial lung abnormalities.The Korean journal of internal medicine · 2025
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Sara TomassettiDept of Experimental and Clinical Medicine, Florence University, Florence, Italy s.tomassetti@gmail.com.ORCID https://orcid.org/0000-0002-4781-6539
Venerino PolettiDept of Diseases of the Thorax, GB Morgagni Hospital, Forlì, Italy.
Claudia RavagliaDept of Diseases of the Thorax, GB Morgagni Hospital, Forlì, Italy.
Nicola SverzellatiDept of Radiology, University of Parma, Parma, Italy.
Sara PiciucchiDept of Radiology, GB Morgagni Hospital, Forlì, Italy.ORCID https://orcid.org/0000-0001-6608-0574
Diletta CozziDept of Emergency Radiology, University Hospital Careggi, Florence, Italy.
Valentina LuzziInterventional Pneumology, Careggi University Hospital, Florence, Italy.
Camilla CominDept of Experimental and Clinical Medicine, Florence University, Florence, Italy.
Athol U WellsRoyal Brompton and Harefield NHS Foundation Trust, London, UK.
Azienda Ospedaliero-Universitaria Careggi · ITOspedale G.B. Morgagni - L.Pierantoni · ITRoyal Brompton & Harefield NHS Foundation Trust · GBUniversity of Florence · ITUniversity of Parma · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The incidental discovery of pre-clinical interstitial lung disease (ILD) has led to the designation of interstitial lung abnormalities (ILA), a radiological entity defined as the incidental finding of computed tomography (CT) abnormalities affecting more than 5% of any lung zone. Two recent documents have redefined the borders of this entity and made the recommendation to monitor patients with ILA at risk of progression. In this narrative review, we will focus on some of the limits of the current approach, underlying the potential for progression to full-blown ILD of some patients with ILA and the numerous links between subpleural fibrotic ILA and idiopathic pulmonary fibrosis (IPF). Considering the large prevalence of ILA in the general population (7%), restricting monitoring only to cases considered at risk of progression appears a reasonable approach. However, this suggestion should not prevent pulmonary physicians from pursuing an early diagnosis of ILD and timely treatment where appropriate. In cases of suspected ILD, whether found incidentally or not, the pulmonary physician is still required to make a correct ILD diagnosis according to current guidelines, and eventually treat the patient accordingly.

Indexed as

Idiopathic Pulmonary FibrosisLung Diseases, InterstitialDisease ProgressionHumansIncidental FindingsLungTomography, X-Ray Computed

Identifiers

PMID35418487
PMCPMC9488620
OpenAlexW4223499716

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.